Skip to content Skip to footer
Subscribe Now
Blueprint Medicines
NEWS

Sanofi to Acquire Blueprint Medicines for ~$9.5B

Shots:Sanofi to acquire Blueprint Medicines, expanding its rare immunological disease portfolioAs per the deal, Blueprint shareholders will receive $129/share in cash (~$9.1B equity value) & one non-tradeable CVR of $2 & $4 per share upon achievement of development & regulatory milestones, respectively, for BLU-808, totaling the deal value up to $9.5B on a…
June 2, 2025

Read more

Vant AI & Blueprint Medicines
NEWS

VantAI and Blueprint Medicines Expands License Agreement to Advance Induced Proximity Drug Discovery

Shots:VantAI and Blueprint Medicines have expanded their 2022 collaboration, adding new drug target programs to develop therapies for critical medical needsAs per the expansion, VantAI will receive up to $1.67B in total including ~$270M R&D and regulatory milestones, and $1.4B commercial milestones across four joint target programs, along with tiered mid-single-digit sales based…
May 21, 2025

Read more

Exclusive_Kenneth-Sake_2025
EXCLUSIVE

Exclusive: Kenneth Sake from Blueprint Medicines in an Enlightening Conversation with PharmaShots

Highlights: Systemic mastocytosis (SM) is a rare disease caused by the abnormal accumulation of mast cells – a key part of the body’s immune systemPeople with SM face potentially debilitating symptoms, such as skin lesions, diarrhoea, bone pain, fatigue and anaphylaxis, which can present challenges across various aspects of patients’ livesFor more than…
March 12, 2025

Read more

Insights+: EMA Marketing Authorization of New Drugs in December 2023
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in December 2023

Shots: The EMA approved 3 BLA while 4 New Chemical Entities in December 2023, leading to treatments for patients and advances in the healthcare industryIn December 2023, the major highlighted drugs were Jempreli to treat dMMR/MSI-H Primary Advanced or Recurrent Endometrial Cancer and Zilbrysq for the treatment of Generalized Myasthenia Gravis  PharmaShots has compiled a list of a…
January 23, 2024

Read more

VIEWPOINTS_Nicolas Paquette-Lamontagne_2023
VIEWPOINTS

Nicolas Paquette-Lamontagne, VP, Medical Affairs at Blueprint Medicines Shares his Views on Clinical Data of Ayvakit for Patients with Systemic Mastocytosis

Shots: Nicolas discussed about Systemic Mastocytosis as a disease and highlighted its epidemiology & other details. He also spoke about the clinical data of avapritinib presented at the ASH’22 Annual Meeting    Nicolas also shared the key findings from the PATHFINDER and EXPLORER trial evaluating avapritinib and the rationale behind conducting two different trials This interview…
February 13, 2023

Read more